Skip to main content

Paul Gillin

Paul Gillin's Public Library

  • The bank's Brian Johnson reckons the driverless world will drive down US auto sales by 40 per cent over the next 25 years, and will force GM and Ford to slash their output, he reckons.
  • Bloomberg says the report, “Disruptive Mobility” predicts over that time the number of cars on US roads will dip below 100 million (down around 60 per cent), and annual sales will fall to 9.5 million (a fall of around 40 per cent from today's levels.
May 13, 15

"FIR B2B #27: Josh Bernoff on Getting the BS Out of Business Communications"

May 13, 15

"as self-driving cars become more prevalent on the roads—the Los Angeles Times spoke to analysts who estimated that 250,000 autonomous vehicles could be sold to consumers in 2025—drivers may start to ask for more detailed information on who, and what, is sharing the road with them."

  • Bryant Walker Smith, an assistant professor at the Center for Internet and Society and a former fellow at the Center for Automotive Research at Stanford (CARS), told Ars last year “As automated systems get more complex, human understanding also gets more complex. For a vehicle to suddenly swerve to the right, a human would have to grab [the steering wheel]... training becomes even more important, and it would also be important for general users.”
  • Nevada, the first state to create rules and regulations governing automated vehicles, requires that all operators report any incident involving a self-driving car and its surroundings.
  • as self-driving cars become more prevalent on the roads—the Los Angeles Times spoke to analysts who estimated that 250,000 autonomous vehicles could be sold to consumers in 2025—drivers may start to ask for more detailed information on who, and what, is sharing the road with them.
May 12, 15

Doximity is an online social networking service for U.S. physicians. Launched in March 2011, Doximity has over 400,000 verified physician members as of December 2014.

  • Starting with Genzyme, we recently launched Cerdelga®, the first oral therapy for Gaucher disease strengthening our Gaucher franchise and reinforcing our leadership position in this business. Genzyme is also making great progress in expanding in Multiple Sclerosis with Aubagio®, our oral MS therapy, and more recently with Lemtrada™, a highly innovative treatment for multiple sclerosis recently launched in the US.
  • n February, Afrezza®, a new inhaled insulin, was launched in the US market. More recently, we also launched Toujeo® in the US in late March, our new once‐daily long‐acting basal insulin, which was approved by the FDA earlier this year and this week by the European regulatory authorities.
  • We are now also looking forward to the expected FDA decision on Praluent™ in July and the potential regulatory approval of Dengue later in the year.

  • Responsible for almost 50% of the French drug maker’s sales, Witz, 47, was recruited last year from GE Healthcare, where she served as CEO of medical diagnostics. Charged with setting the group’s strategic direction, the biologist also has direct oversight of key growth businesses like diabetes, oncology, and consumer healthcare.

  • Pascale has long promoted women’s career advancement and female leadership. In 2014, Pascale was listed as one of Fortune’s Most Powerful Women in EMEA. At Sanofi, she is engaged in the Women’s Forum, a global group supported by Sanofi and other companies promoting the advancement of women worldwide via business and social networks.
  • Pascale spent 17 years at GE Healthcare, most recently as the President and CEO of the Medical Diagnostics business. She started her career in a molecular biology research lab in Strasbourg, France
1 - 20 of 7280 Next › Last »
20 items/page

Highlighter, Sticky notes, Tagging, Groups and Network: integrated suite dramatically boosting research productivity. Learn more »

Join Diigo